Oppenheimer Maintains Outperform on Pliant Therapeutics, Raises Price Target to $52
Portfolio Pulse from richadhand@benzinga.com
Oppenheimer analyst Jeff Jones has maintained an Outperform rating on Pliant Therapeutics (NASDAQ:PLRX) and raised the price target from $51 to $52.
August 10, 2023 | 3:50 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Pliant Therapeutics' Outperform rating has been maintained by Oppenheimer, with a raised price target from $51 to $52.
The maintained Outperform rating and increased price target by Oppenheimer indicates a positive outlook for Pliant Therapeutics. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100